# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Kristen Kluska reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Overweight and maintains $7 p...
Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $7 price target.
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of...
Jefferies analyst Eun Yang assumes Taysha Gene Therapies (NASDAQ:TSHA) with a Buy rating and raises Price Target to $8.
Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $7 price target.
RMAT designation follows FDA's review of available safety and efficacy data from the first three patients dosed with the lo...
Cantor Fitzgerald analyst Kristen Kluska reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Overweight and maintains $7 p...
Cantor Fitzgerald analyst Kristen Kluska reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Overweight and maintains $7 p...